Floatz Rating
B59/100
Confidence
Indicative
Sponsor
池畔
Modality
UNKNOWN
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
52Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05969847CT.gov Organ Preservation Following Enverolimab-based Total Neoadjuvant Therapy for Locally Advanced Very Low Rectal Cancer | — | Not Yet Recruiting | — | — | — |
NCT05858567CT.gov Total Neoadjuvant Therapy With Short-course Radiation Followed by Envafolimab Plus CAPEOX for MSS Locally Advanced Ultra Low Rectal Adenocarcinoma | — | Unknown | — | — | — |
NCT05752136CT.gov Preoperative Short-course Radiation Followed by Envafolimab Plus CAPEOX for MSS Locally Advanced Rectal Adenocarcinoma | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Rectal Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Envafolimab (this asset) | 池畔 | P3 | B · 59 |
| Capecitabine | Gustave Roussy, Cancer Campus, Grand Paris | P4 | BBB |
| Oxaliplatin | Gustave Roussy, Cancer Campus, Grand Paris | P3 | BBB |
| Floxuridine | City of Hope Medical Center | P2 | BBB |
| Fluorouracilum | Gustave Roussy, Cancer Campus, Grand Paris | P3 | BBB |
| Irinotecan | SCRI Development Innovations, LLC | P3 | BB |
| Cetuximab | Tang-Du Hospital | P2 | BB |
| Panitumumab | Grupo Espanol Multidisciplinario del Cancer Digestivo | P2 | BB |
| Pertuzumab | SWOG Cancer Research Network | P2 | BB |
+42 more in the Rectal Carcinoma cohort
Other indications for Envafolimab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Renal Cell Carcinoma | — | P2 | B · 60 |
| Non-Small Cell Lung Carcinoma | — | P3 | B · 58 |
| Hepatocellular Carcinoma | — | P2 | CCC · 55 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Envafolimab in Rectal Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/envafolimab-rectal-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →